RMD – Macquarie rates the stock as Underperform

By Broker News | More Articles by Broker News

Macquarie has long maintained the mantra that ResMed’s valuation, now 36.8x forward earnings and a 38% premium to medical device peers, ascribes limited medium-term risk in relation to reimbursement changes or the longer-term impact of competing technologies. Underperform retained.

Ahead of this week’s result release, the broker has made minor adjustments to revenue and growth assumptions and currency. Target rises to $17.00 from $16.50.

Sector: Health Care Equipment & Services.

Target price is $17.00.Current Price is $23.90. Difference: ($6.90) – (brackets indicate current price is over target). If RMD meets the Macquarie target it will return approximately -41% (excluding dividends, fees and charges – negative figures indicate an expected loss).


Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →